The Technical Analyst
Quoin Pharmaceuticals, [QNRX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Quoin Pharmaceuticals, Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.77% $0.695
America/New_York / 19 apr 2024 @ 14:33
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.686 mill |
| EPS: | -9.64 |
| P/E: | -0.0700 |
| Earnings Date: | May 05, 2024 |
| SharesOutstanding: | 0.987 mill |
| Avg Daily Volume: | 0.620 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0700 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0700 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.478 - 0.922 ( +/- 31.71%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-10-26 | Sember Michael T | Buy | 7 652 | Share Option (Right to Buy) |
| 2023-10-26 | Dunn Gordon | Buy | 51 149 | Share Option (Right to Buy) |
| 2023-10-26 | Myers Michael | Buy | 80 965 | Share Option (Right to Buy) |
| 2023-10-26 | Culverwell Anthony James | Buy | 7 652 | Share Option (Right to Buy) |
| 2023-10-26 | Cooper Joseph Patrick | Buy | 7 652 | Share Option (Right to Buy) |
| INSIDER POWER |
|---|
| -99.96 |
| Last 24 transactions |
| Buy: 251 340 | Sell: 1 792 856 400 |
Forecast:
16:00 - $0.695
Live Trading Signals (every 1 min)
Forecast
1: 14:42 - $0.701
Forecast 2: 15:32 - $0.698
Forecast 3: 16:00 - $0.695
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.695 (-4.77% ) |
| Volume | 0.0372 mill |
| Avg. Vol. | 0.620 mill |
| % of Avg. Vol | 6.00 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For QNRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
QNRX
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Latest Press Releases
2024-03-13 16:05:00 - Press Release
Quoin Pharmaceuticals Provides Corporate Update And Announces Fourth Quarter And 2023 Financial Results
Company reported positive initial clinical data for qrx003 from first six evaluable subjects in ongoing open-label netherton syndrome study with positive benefits observed across a number of clinical endpoints
2024-03-07 16:05:00 - Press Release
Quoin Pharmaceuticals Announces Fourth Quarter And 2023 Financial Results And Corporate Update Conference Call To Be Held On Thursday March 14th At 8:30 Am Et
Ashburn, va., march 07, 2024 (globe newswire) -- quoin pharmaceuticals ltd. (nasdaq: qnrx) (the “company” or “quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the company plans to release its fourth quarter and 2023 financial results after the market closes on wednesday, march 13, 2024.
2024-02-14 09:00:00 - Press Release
Skinvisible Announces Significant Progress In Licensee's Clinical Trials For Invisicare Formulation Targeting Nethertons Syndrome
Las vegas, nv / accesswire / february 14, 2024 / skinvisible, inc. ("skinvisible") (otcqb:skvi) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, quoin pharmaceuticals, inc. ("quoin") (nasdaq:qnrx). the trials focus on the innovative formulation "qrx003," powered by skinvisible's invisicare® proprietary drug delivery technology, to address the challenges of netherton syndrome ("ns").
2023-12-13 12:12:28 - Press Release
Prism Marketview Biotech In Motion Spotlight: Quoin Receives Fda Clearance For Netherton Syndrome Clinical Optimization Plan
New york, ny, december 13, 2023 – quoin pharmaceuticals (nasdaq:qnrx) has received u.s. food and drug administration (fda) clearance to implement several protocol amendments to its two ongoing clinical trials for qrx003, which is a potential treatment for netherton syndrome, a rare genetic skin disease for which there is no cure and no approved treatments.
2023-12-13 08:30:00 - Press Release
Quoin Pharmaceuticals Announces Fda Clearance Of Clinical Optimization Plan For Qrx003 For Netherton Syndrome
Positive initial data and clean safety profile catalyze optimization plan size of both ongoing clinical trials significantly increased lower dose eliminated from blinded trial dosing frequency changed to twice-daily from once-daily for both trials
Latest News
2024-03-07 16:05:00 - GlobeNewsWire
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its fourth quarter and 2023 financial results after the market closes on Wednesday, March 13, 2024.
2024-03-05 08:34:01 - InvestorPlace
Why Is Quoin Pharmaceuticals (QNRX) Stock Down 50% Today?
Quoin Pharmaceuticals (NASDAQ: QNRX ) stock is falling on Tuesday after the clinical-stage specialty pharmaceutical company announced details of a public offering for its shares. The public offering has Quoin Pharmaceuticals selling 4,062,500 shares of QNRX stock for $1.60 each.
2023-11-09 10:51:04 - Seeking Alpha
Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript
2023-11-03 08:41:00 - GlobeNewsWire
Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET
ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quarter 2023 financial results after the market closes on Wednesday, November 8, 2023.
2023-08-07 01:24:01 - Seeking Alpha
Quoin Pharmaceuticals, Ltd. (QNRX) Q2 2023 Earnings Call Transcript
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX ) Q2 2023 Results Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Co-Founder, Chairman and Chief Executive Officer Conference Call Participants Naz Rahman - Maxim Group Laura Suriel - Alliance Global Partners Operator Good morning.
2023-07-17 08:18:38 - InvestorPlace
Why Is Quoin Pharmaceuticals (QNRX) Stock Down 90% Today?
Quoin Pharmaceuticals (NASDAQ: QNRX ) stock is taking a massive beating on Monday as the company prepares for an ADS ratio change. According to a filing from Quoin Pharmaceuticals, the company is enacting an ADS ratio change that will switch its stock from one for 5,000 shares to one for 6,000 shares.
2023-03-02 16:05:00 - GlobeNewsWire
Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET
ASHBURN, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company intends to release its 2022 fourth quarter and year-end financial results after the market closes on Wednesday, March 8, 2023.
2022-11-10 14:38:05 - Seeking Alpha
Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2022 Earnings Call Transcript
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX ) Q3 2022 Earnings Conference Call November 10, 2022 10:00 AM ET Company Participants Gordon Dunn - CFO Michael Myers - CEO Conference Call Participants Aydin Huseynov - Ladenburg Thalmann James Molloy - Alliance Global Partners Naz Rahman - Maxim Group Operator Good morning and welcome to the Quoin Pharmaceuticals Limited Third Quarter Financial Results and Business Update Call.
2022-11-01 08:30:00 - GlobeNewsWire
Quoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10th
ASHBURN, Va., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that its third quarter 2022 financial results will be reported on Thursday, November 10, 2022 before the open of the financial markets. Management will also host a webcast and conference call on November 10, 2022 at 8:30 a.m. ET to discuss the results and provide a corporate update.
2022-10-19 14:12:01 - PennyStocks
10 Top Penny Stocks To Buy According To Wall Street Analysts In 2022
Penny stocks to buy according to analysts in 2022. The post 10 Top Penny Stocks To Buy According To Wall Street Analysts In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.